發(fā)布時間：2018-03-30 05:29

  本文選題：檢查點　切入點：黑色素瘤　出處：《中國免疫學雜志》2017年04期

【摘要】：正免疫檢查點阻斷治療是當今備受矚目的新興腫瘤治療方式。不同于以往其他治療方式,免疫檢查點抑制劑靶向機體免疫系統(tǒng)而非腫瘤細胞,旨在恢復(fù)并促進效應(yīng)T細胞特異性識別和殺傷腫瘤細胞的功能,系統(tǒng)性增強全身的抗腫瘤免疫反應(yīng),因而代表了當前腫瘤治療模式的轉(zhuǎn)變。迄今多個臨床試驗已證實免疫檢查點抑制劑在晚期黑色素瘤、非小細胞肺癌(Non-small-cell lung cancer,NSCLC)及膀胱
[Abstract]:The positive immunological checkpoint blocking therapy is one of the most popular methods for the treatment of neoplasms. Unlike other treatments, immunocheckpoint inhibitors target the body's immune system rather than tumor cells. The aim is to restore and promote the function of specific recognition and killing of tumor cells by effector T cells, and to systematically enhance the anti-tumor immune response of the whole body. So far, a number of clinical trials have confirmed immunological checkpoint inhibitors in advanced melanoma, non-small- cell lung cancer-NSCLC) and bladder.
【作者單位】： 上海交通大學醫(yī)學院附屬仁濟醫(yī)院婦產(chǎn)科上海市婦科腫瘤重點實驗室;
【基金】：國家自然科學基金面上項目(81472843) 上海市科學技術(shù)委員會上海市科研計劃項目(14ZR1424700)資助
【分類號】：R730.51

【相似文獻】

相關(guān)期刊論文 前1條

1 付s，

本文編號：1684568